Liu Yong, Xie Cong-Liang, Qiu Yuan-Zheng, Tian Yong-Quan, Zhang Xin, Huang Dong-Hai, Zhou Xiao-Juan, Tan Ping-Qing, Yu Chang-Yun, Qi Lin, Li Bo, Xiao Jian-Yun
Department of Otorhinolaryngology, Xiangya Hospital, Central South University, Changsha Hunan 410008, China.
Zhonghua Zhong Liu Za Zhi. 2012 Feb;34(2):132-6. doi: 10.3760/cma.j.issn.0253-3766.2012.02.011.
To evaluate the expression of HMGB1 protein in tissue specimens of laryngeal squamous cell carcinoma (LSCC) and adjacent normal mucosa, and explore the correlation of HMGB1 protein expression with clinicopathologic features and prognosis in LSCC.
Ninty-three cases of LSCC and 5 cases of adjcent mucosal tissue samples were included in this study. Immunohistochemical staining was performed on paraffin-embedded tissue specimens to examine the HMGB1 protein expression. The data were futher correlated with the clinicopathological features and prognosis of the LSCC patients.
The positive rates of HMGB1 expression in LSCC specimens was 87.1%, significantly higher than that in the adjcent normal mucosa samples (46.7%, P = 0.001), and its overexpresion was closely correlated with T stage (Chi2 = 10.878, P = 0.004), clinical stage (Chi2 = 21.115, P < 0.01), metastasis (Chi2 = 28.298, P < 0.01) and recurrence (Chi2 = 14. 923, P = 0.001) in patients with LSCC. Patients with HMGB1 overexpression had both poorer disease-free survival and poorer overall survival compared with that in patients with low HMGB1 expression (Chi2 = 13.815, Chi2 = 11.912; Both P < 0.01). Univariate and multivariate Cox regression analyses revealed that HMGBI expression is an independent prognostic factor for patients with LSCC.
The results of this study demonstrate that HMGB1 protein expression is significantly increased in LSCC tissues, and HMGB1 protein overexpression is associated with a poorer prognosis in patients with LSCC. These results suggest that HMGB1 may play a critical role in the initiation and progression of LSCC, implicating HMGB1 may become a valuable marker for the prediction of prognosis in patients with LSCC.
评估高迁移率族蛋白B1（HMGB1）蛋白在喉鳞状细胞癌（LSCC）组织标本及癌旁正常黏膜中的表达情况，并探讨HMGB1蛋白表达与LSCC临床病理特征及预后的相关性。
本研究纳入93例LSCC病例及5例癌旁黏膜组织样本。对石蜡包埋组织标本进行免疫组织化学染色，检测HMGB1蛋白表达。进一步将数据与LSCC患者的临床病理特征及预后相关联。
LSCC标本中HMGB1表达的阳性率为87.1%，显著高于癌旁正常黏膜样本（46.7%，P = 0.001），其过表达与LSCC患者的T分期（χ2 = 10.878，P = 0.004）、临床分期（χ2 = 21.115，P < 0.01）、转移（χ2 = 28.298，P < 0.01）及复发（χ2 = 14.923，P = 0.001）密切相关。与低HMGB1表达患者相比，HMGB1过表达患者的无病生存期和总生存期均较差（χ2 = 13.815，χ2 = 11.912；均P < 0.01）。单因素和多因素Cox回归分析显示，HMGB1表达是LSCC患者的独立预后因素。
本研究结果表明，LSCC组织中HMGB1蛋白表达显著增加，HMGB1蛋白过表达与LSCC患者预后较差相关。这些结果提示，HMGB1可能在LSCC的发生和发展中起关键作用，意味着HMGB1可能成为预测LSCC患者预后的有价值标志物。
